Working Together · Building the Future
Featured Research Partner
SAFE Pharmaceutical Beijing
An established one-stop innovative-drug CRO platform (founded 2016), covering GLP nonclinical safety evaluation (NMPA 10 full accreditations), pharmacology, pharmacokinetics, antibody discovery, central laboratory (GCP/GLP/CAP/ISO 15189) and radiopharmaceutical CRDMO — holding NMPA & OECD GLP, AAALAC, CMA, A2LA ISO 15189 and CAP accreditations. Global footprint: Beijing functional lab, four GLP bases in Gu'an/Suzhou/Shenzhen/Wuxi, plus US node. Specialty platforms include radiopharmaceuticals, ophthalmology, inhalation, CNS/neurological, cell & gene therapy, PROTAC/ADC/mRNA. Seno.Bio's deep partnership with the Yangtze River Delta National Innovation Center for Drug Safety Evaluation Technology and SAFE Pharmaceutical delivers the drug path through a combined structure under one contract — a single accountable partner across the full GLP-to-CRO chain.
See how the drug-side path works with us →Featured Commercialization Partner
Jointown Pharmaceutical Group (SSE: 600998)
One of China's largest pharmaceutical and medical device distributors, with 2025 revenue above RMB 161.3 billion. Through this partnership, devices manufactured on our platform can enter Jointown's nationwide distribution network directly — reaching over 100,000 pharmacies and more than 10,000 county-level and above public hospitals, without hunting for provincial distributors or building a sales organization from scratch.
Academic & Research Institutions
Innovation Platforms & Industry Partners
Partnership means more than a service relationship
Through Growth Co-Investment, the platform builds deep equity alignment with strong projects, creating a win-win ecosystem. We're not a vendor and a customer — we're industrial partners moving in the same direction.
Discuss a Partnership